...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Radiotherapy and oncology: Journal of the European Society for Therapeutic Radiology and Oncology >Stereotactic body radiotherapy for localized prostate cancer: Pooled analysis from a multi-institutional consortium of prospective phase II trials
【24h】

Stereotactic body radiotherapy for localized prostate cancer: Pooled analysis from a multi-institutional consortium of prospective phase II trials

机译：立体定向放射疗法治疗局限性前列腺癌：前瞻性II期临床试验的多机构联合体的汇总分析

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Purpose The effectiveness of stereotactic body radiotherapy (SBRT) for localized prostate cancer is tested. Methods and materials A total of 1100 patients with clinically localized prostate cancer were enrolled in separate prospective phase 2 clinical trials of SBRT from 8 institutions during 2003-11 and pooled for analysis. SBRT using the CyberKnife delivered a median dose of 36.25 Gy in 4-5 fractions. Patients were low-risk (58%), intermediate-risk (30%) and high-risk (11%). A short-course of androgen deprivation therapy (ADT) was given to 14%. PSA relapse defined as a rise >2 ng/ml above nadir was analyzed with the Kaplan Meier method. Results With a median follow-up of 36 months there were 49 patients with PSA failure (4.5%), 9 of whom were subsequently determined to be benign PSA bounces. The 5-year biochemical relapse free survival (bRFS) rate was 93% for all patients; 95%, 83% and 78% for GS ≤6, 7 and ≥8, respectively (p = 0.001), and 95%, 84% and 81% for low-, intermediate- and high-risk patients, respectively (p < 0.001). No differences were observed with ADT (p = 0.71) or as a function of total dose (p = 0.17). A PSA bounce of >0.2 ng/ml was noted among 16% of patients. For 135 patients possessing a minimum of 5 years follow-up, the 5-year bRFS rate for low- and intermediate-risk patients was 99% and 93%, respectively. Conclusion PSA relapse-free survival rates after SBRT compare favorably with other definitive treatments for low and intermediate risk patients. The current evidence supports consideration of SBRT among the therapeutic options for these patients.
机译：目的测试立体定向放射疗法（SBRT）对局部前列腺癌的有效性。方法和材料2003-11年，来自8个机构的总共1100例临床局限性前列腺癌患者参加了单独的SBRT前瞻性2期临床试验，并进行分析。使用射波刀的SBRT的中位数剂量为4-5份，为36.25 Gy。低危（58％），中危（30％）和高危（11％）。短程雄激素剥夺治疗（ADT）占14％。通过Kaplan Meier方法分析了PSA复发，定义为高于最低谷2 ng / ml。结果平均随访36个月，有49例PSA衰竭患者（4.5％），其中9例随后被确定为良性PSA反弹。所有患者的5年生化无复发生存率（bRFS）为93％; GS ≤6、7和≥8的分别为95％，83％和78％（p = 0.001），低，中，高风险患者分别为95％，84％和81％（p < 0.001）。 ADT（p = 0.71）或总剂量的函数（p = 0.17）未观察到差异。在16％的患者中发现PSA反弹> 0.2 ng / ml。对于135位至少接受5年随访的患者，低危和中危患者的5年bRFS发生率分别为99％和93％。结论SBRT后PSA的无复发生存率优于其他确定的中低风险患者治疗方法。目前的证据支持在这些患者的治疗选择中考虑SBRT。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号